KPV Research: What 184 Studies Show (2026) | RetatrutideCompare

KPV — 184 studies indexed on PubMed. Anti-inflammatory; suppresses NF-κB, IL-1β, TNF-α in gut and skin epithelial models without binding melanocortin receptors. Half-life: minutes (oral peptide stable in gut). FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on KPV?

There are approximately 184 studies indexed on PubMed that mention KPV (α-MSH (11-13), Lys-Pro-Val), based on a search last updated 2026-06-18.

Is KPV FDA-approved?

FDA status: Not FDA-approved.

How does KPV work?

Anti-inflammatory; suppresses NF-κB, IL-1β, TNF-α in gut and skin epithelial models without binding melanocortin receptors.

Anti-inflammatory; suppresses NF-κB, IL-1β, TNF-α in gut and skin epithelial models without binding melanocortin receptors.

Reference facts

Also known as
α-MSH (11-13), Lys-Pro-Val
Category
Healing & Tissue Repair
Mechanism of action
Anti-inflammatory; suppresses NF-κB, IL-1β, TNF-α in gut and skin epithelial models without binding melanocortin receptors.
Targets
NF-κB pathway
Indications under research or approved
Research — IBD, atopic dermatitis
Regulatory status (reference entry)
Not FDA-approved
Half-life
minutes (oral peptide stable in gut)
Sequence
KPV
Sequence notes
C-terminal tripeptide of α-melanocyte-stimulating hormone, retains anti-inflammatory activity without melanogenesis.
Molecular weight (Da)
343
First reported
1982

Primary References

Explore research articles about KPV

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.